HER2 positive metastatic breast cancer: What happens after first line failure?

QR Code

HER2 positive metastatic breast cancer: What happens after first line failure?

For women with metastatic HER2 positive breast cancer, the introduction of trastuzumab into routine practice was transformative. More recently, the addition of pertuzumab has further improved the outlook. However in almost all cases, the disease unfortunately progresses. Much research has gone into...

Full description

Bibliographic Details
Main Author:	Chan, Arlene
Format:	Journal Article
Published:	Cancer Council Australia 2016
Online Access:	http://hdl.handle.net/20.500.11937/58480

Similar Items

Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer
by: Chan, Arlene, et al.
Published: (2010)

Phase II study of a triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer
by: Chan, Arlene, et al.
Published: (2013)

Neratinib after trastuzumab in patients with HER2-positive breast cancer - Author's reply
by: Chan, Arlene, et al.
Published: (2016)

Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer
by: Miles, D., et al.
Published: (2013)

Neratinib in HER-2-positive breast cancer: Results to date and clinical usefulness
by: Chan, Arlene
Published: (2016)

AVEREL: A Randomised Phase 111 Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER-2Positive Locally Recurrent/Metastatic Breast Cancer
by: Gianni, L., et al.
Published: (2013)

Capecitabine and vinorelbine in metastatic breast cancer
by: Chan, Arlene, et al.
Published: (2009)

Phase II, open-label trial of lapatinib and vinorelbine in women with previously treated HER2-positive metastatic breast cancer
by: Chan, Arlene, et al.
Published: (2014)

TILs in metastatic breast cancer—no surprises, but more questions
by: Chan, Arlene
Published: (2017)

Adjuvant trastuzumab in HER2-positive breast cancer.
by: Slamon, D., et al.
Published: (2011)

Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy for HER2-Negative Metastatic Breast Cancer
by: Cinieri, S., et al.
Published: (2017)

Prevalence and management of HER2/neu-positive early breast cancer in a single institution following availability of adjuvant trastuzumab
by: Chan, Arlene, et al.
Published: (2012)

A retrospective study investigating the rate of HER2 discordance between primary breast carcinoma and locoregional or metastatic disease
by: Chan, Arlene, et al.
Published: (2012)

Evaluating the expression of HMGCR in HER2 negative and HER2 positive breast cancer
by: Drahman, Rosmaizan
Published: (2022)

Expression of HER4 isoforms and HER4 localisation in HER2 negative breast cancer cell lines
by: Ali, Nursyazana Aqilah
Published: (2021)

Cytoplasmic and nuclear HER4 expression in HER2 negative breast cancer cell lines
by: Siti Norasikin Mohd Nafi,, et al.
Published: (2022)

Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer
by: Dent, R., et al.
Published: (2013)

RESILIENCE: Phase III Randomized, Double-Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2-Negative Breast Cancer
by: Baselga, J., et al.
Published: (2017)

Randomized Phase 111 Placebo-Controlled Trial of Letrozole Plus Oral Temsirolimus As First-Line Endrocrine Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
by: Wolff, A., et al.
Published: (2013)

Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer
by: Wolff, A., et al.
Published: (2013)

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer
by: Miles, D., et al.
Published: (2010)

Biological characterisation of HER2 amplified breast cancer
by: Barros, Fabrício Félix Tabuada
Published: (2013)

The role of HER family signalling in breast cancer
by: Kuruppu, Anchala
Published: (2016)

Phase 1b dose-finding study of motesanib with docetaxel or paclitaxel in patients with metastatic breast cancer
by: De Boer, R., et al.
Published: (2012)

Pigment epithelium-derived factor and menopause in metastatic breast cancer
by: Brook, Naomi Louise
Published: (2022)

Cediranib in combination with fulvestrant in hormone-sensitive metastatic breast cancer: a randomized Phase 11 study
by: Hyams, D., et al.
Published: (2013)

Glutamate regulation of Voltage-Gated Sodium Channels (VGSCS) in breast cancer cell lines of different metastatic potential
by: Azahar, Irfan Irsyad
Published: (2022)

Expression of foxp3 tumour infiltrating lymphocytes in her2 positive breast cancer and their association with clinicopathological features
by: Hashim, Sobry
Published: (2023)

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
by: Chan, Arlene, et al.
Published: (2016)

Evaluation of fatty liver in breast cancer patients and its metastatic potential
by: Ahmad, Nor Hayati
Published: (2021)

Lombok, Indonesia Earthquake: What Happened and Why?
by: Harun, Hasnida, et al.
Published: (2020)

Computational pathology and deciphering the complexity of HER2 expression in breast cancer
by: Atallah, Nehal Mohammed
Published: (2025)

What happens after ERP implementation : understanding the impact of IS sophistication, interdependence and differentiation on plant-level outcomes / Chan Ming Ming
by: Chan, Ming Ming
Published: (2010)

Comparison of tumour biomarker HER-2/neu (C-erbB-2) before and after surgery in breast cancer patients
by: Aung, Sanda, et al.
Published: (2014)

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
by: Martin, M., et al.
Published: (2017)

Role of novel therapeutic agents in modulating invadopodia formation in metastatic breast cancer
by: Siti Nor Aini Harun,, et al.
Published: (2020)

Malezya'da neler oluyor? (What is happening in Malaysia?)
by: Kayadibi, Saim
Published: (2015)

Obesity prevention and intervention: what's happening in the East Midlands?
by: Cross-Bardell, Laura, et al.
Published: (2017)

What happens when you apply for a job?
by: Holtrop, Djurre
Published: (2019)

The Fly-In, Fly Out Debate: What Happens to the Communities?
by: Burns, Sharyn
Published: (2013)

Cannot write session to /tmp/vufind_sessions/sess_4k1m9vntaiv2v0l44d0n40o61j